

Triple therapy combinations for the treatment of type 2 diabetes – a network meta-analysis

Crystal Man Ying Lee^a, Mark Woodward^{b,c}, Stephen Colagiuri^a

^a The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, Level 2 Charles Perkins Centre D17, University of Sydney, NSW 2006, Australia

^b The George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK

^c The George Institute for Global Health, PO Box M201, Missenden Road, Camperdown, NSW 2050, Australia

Running title: Triple therapy for treatment of diabetes

Word count: 3694

Number of figures and tables: 5

Correspondence:

Crystal Lee

Email: crystal.lee@sydney.edu.au

Abstract

Aim: To estimate and compare the results from all randomized trials of triple combinations of anti-diabetes therapies that reported the reduction of glycated haemoglobin (HbA1c) and associated effects on body weight and hypoglycaemia.

Methods: PubMed and the Cochrane Library were searched for trials with at least one study arm on triple therapy and which reported the differences in mean change in HbA1c between two study arms. These were included in a network meta-analysis.

Results: Altogether, 15182 participants from 40 trials with treatment duration of 6 to 12 months were included. Compared with none/placebo added to dual therapy, the addition of a drug therapy from six of eight drug classes to existing dual therapy resulted in significant additional mean reductions in HbA1c from -0.56% (-6.2 mmol/mol; dipeptidyl peptidase 4 inhibitors) to -0.94% (-10.3 mmol/mol; thiazolidinediones). Of the six drug classes, three were associated with less favourable weight change and two were associated with more favourable weight change when compared with none/placebo added to dual therapy. Furthermore, five drug classes were associated with greater odds of hypoglycaemia. Similar results were observed in analyses of studies with 6 months treatment duration and after excluding study arms that contained insulin.

Conclusions: Overall triple therapy combinations were similar in improving diabetes control although there were some differences in adverse effects. By balancing the risks and benefits of each therapy, the estimates of pairwise comparisons of triple therapies for HbA1c, body weight and hypoglycaemia provided in this study may further inform evidence based practice.

Keywords: type 2 diabetes; treatment; pharmacotherapy.

Introduction

In clinical practice, glucose-lowering pharmacotherapy is prescribed when lifestyle modification is not effective in the management of type 2 diabetes. If glycaemic control becomes inadequate with a single therapy, a second and then a third therapy may be added to the treatment, while reinforcing the importance of lifestyle modification [1]. A network meta-analysis published in 2011 compared the effects of a number of therapies added to metformin (MET) and sulfonylurea (SU) for the treatment of type 2 diabetes [2]. However, triple therapy combinations other than those that include both MET and SU are increasingly used and may result in greater reduction in glycated haemoglobin (HbA1c). A randomised trial that compared the triple combinations MET/SU/DPP-4 (dipeptidyl peptidase 4 inhibitors) and MET/DPP-4/INS (insulin) reported a -0.40% [95% confidence intervals: -0.66, -0.15] (-4.4 [-7.3, -1.7] mmol/mol) greater reduction in HbA1c with MET/DPP-4/INS after a six month treatment period [3]. Moreover, a third therapy is usually added to the existing dual therapy treatment and because of individualized treatment plans, patients may not necessarily be taking the MET/SU dual therapy combination. Therefore, we aimed to estimate and compare the effect of all triple therapy combinations that have been studied in clinical trials on glycaemic control as assessed by HbA1c and to examine the effect on weight changes and hypoglycaemia to further inform evidence based practice in the management of type 2 diabetes.

Materials and methods

We consulted the PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses checklist in preparation of this review [4].

Literature search

We searched PubMed and the Cochrane Library for relevant studies that were published to 8th April 2015, using a combination of key words and MeSH terms: “biguanides”, “metformin”, “sulfonamides”, “sulfonylureas”, “glibenclamide”, “gliclazide”, “glimepiride”, “glipizide”, “glyburide”, “dipeptidyl peptidase 4 inhibitors”, “DPP-4 inhibitors”, “gliptins”, “alogliptin”, “linagliptin”, “saxagliptin”, “sitagliptin”, “vildagliptin”, “GLP-1 receptor agonists”, “incretin analogues”, “albiglutide”, “exenatide”, “liraglutide”, “lixisenatide”, “sodium glucose co-transporter inhibitors”, “SGLT2 inhibitors”, “canagliflozin”, “dapagliflozin”, “empagliflozin”, “alpha glucosidase inhibitors”, “acarbose”, “miglitol”, “voglibose”, “thiazolidinediones”, “TZD”, “glitazones”, “pioglitazone”, “rosiglitazone”, “insulin”, “meglitinide”, “nateglinide”, “repaglinide”, “type 2 diabetes”, and “clinical trial”. The full electronic search strategy is provided in Appendix. References from relevant studies and reviews were inspected to identify other potential studies. No language restriction was applied.

Study selection, data extraction, and quality assessment

Studies were included if they fulfilled the following criteria: randomised trials in adults (aged \geq 18 years) with type 2 diabetes; at least one study arm involved triple therapy; at least two study arms were on different drug class combinations; and reported the mean change and its variability (i.e. standard deviation, standard error, or 95% confidence interval) in HbA1c from

baseline for each study arm or the difference in mean change and its variability between two study arms. Attempts were made to include studies that did not report the required summary statistics on HbA1c by contacting the corresponding authors of these studies. Drug classes available for the treatment of type 2 diabetes include MET, SU, DPP-4, INS, glucagon-like peptide-1 receptor agonist (GLP-1), sodium-glucose linked transporter protein 2 inhibitors (SGLT2), alpha glucosidase inhibitors (AGI), thiazolidinediones (TZD), and meglitinides (MEG).

Studies were excluded if the treatment period was less than 20 weeks, since adjustments to dosages, such as for INS, may take place in the first few weeks of the treatment period and change in HbA1c may not be noticeable in the first three months due to the 120 day life span of red blood cells. Studies with treatment duration greater than 54 weeks that did not report interim results during the first 6 to 12 months of treatment, sample size less than 30 per study arm, or compared a triple therapy arm with a monotherapy arm were also excluded. Studies that combined participants on different background therapy combinations during the treatment period were excluded unless mean changes in HbA1c were reported for the subgroups that were on the same background therapy combinations.

Literature search and data extraction were conducted by C.M.Y.L in consultation with S.C. Information extracted from each study included study characteristics (name of primary author, year of publication, location of trial, drug class combinations, sample size and details of medications used for each study arm, treatment duration, and analysis set used), baseline characteristics of studied populations (proportion of females, mean age, mean body mass index,

mean duration of diabetes, and mean HbA1c), and study outcomes (change in HbA1c, change in body weight, and number of participants experienced at least mild hypoglycaemia during treatment period). For studies that have multiple follow-up visits, data collected closest to 6 months after the start of treatment were included in the analysis. For multi-arm studies that included study arms that were assigned the same drug class combinations but at different dosages for one of the drugs, the study arm allocated the dosage that was most commonly used in other studies for that drug was included in the analysis. The Jadad Scale was used to assess the quality of the included studies [5].

Data analysis

We estimated the mean difference in HbA1c between each drug class added to an existing dual therapy compared to adding a nothing or adding a placebo (none/placebo) to an existing dual therapy to determine if any of the third therapy added to existing dual therapy is superior in reducing HbA1c.. Since not all triple therapies have been compared in randomised trials, a multivariate network meta-analysis was employed instead of a traditional pairwise meta-analysis. Multivariate network meta-analysis can provide estimates for all pairwise comparisons that are linked to a network of trials through utilising both direct evidence obtained from studies directly comparing drug class combinations and indirect evidence estimated through a common comparator [6]. Furthermore, information from multi-arm studies can be included in the network meta-analysis, thus increasing the number of studies that can be included in the analysis. Estimates of all pairwise comparisons of triple therapies were provided to assist in the selection of the drug class that appears most appropriate as add on to existing dual therapy. In

order to assess the adverse effects of the triple therapy combinations, the analyses were repeated for difference in mean change in body weight reported as kilograms and for difference in the proportion of participants who experienced hypoglycaemia reported as odds ratios. Since the level of HbA1c may be different at 6 months and 12 months after the start of treatment, a sensitivity analysis was conducted restricted to studies with about 6 months (20-30 weeks) treatment duration. Analyses were also repeated after excluding study arms that contained insulin, and after removing studies that were rated “poor” based on the Jadad Scale.

Multiple-outcomes meta-analysis was conducted using *network*, a suite of Stata commands for network meta-analysis within a frequentist framework [7]. A network plot was used to assess the geometry of the network [4]. Each node represents a drug class added to existing dual therapy and direct comparisons between drug classes are represented by connections between the nodes. The number of studies available per direct comparison is provided in the network. The size of the node reflects the number of studies available for the drug class. Estimates derived from consistency models are reported. Overall inconsistency across comparisons between direct and indirect evidence were tested using the design-by-treatment interaction inconsistency model. Relative rankings of the therapy combinations were estimated using the surface under the cumulative ranking curve (SUCRA). SUCRA is the cumulative probabilities of a treatment to achieve each of all possible ranks out of all competing treatments [8]. For instance, if three treatments were compared, SUCRA for treatment 1 would be the cumulative probabilities of treatment 1 ranking first out of all three treatments, ranking second out of all

three treatments, and ranking third out of all three treatments. All statistical analyses were performed using Stata/IC 12.0 for Windows (Stata Corp LP., College Station, TX, USA).

Results

A total of 11666 titles and abstracts were screened after duplicates were removed (Supplementary Figure 1). Of these, 137 articles were retrieved to assess their eligibility and 87 articles were removed based on our inclusion and exclusion criteria. Nine authors were contacted for missing data; three authors provided additional information and missing data from two studies were obtained from a published meta-analysis. A further six articles were removed; four trials had sample size less than 30 per arm and two trials were included in other publications. Therefore, 40 studies were included in the network meta-analysis.

Characteristics of included studies

Altogether, 15182 participants with type 2 diabetes from 40 trials with treatment duration ranging from 20 to 54 weeks (90% of trials with treatment duration of 6 months (20-30 weeks)) were available for analysis (Table 1). The characteristics of the studied populations varied with baseline mean values ranging from 52.6 to 65.3 years (median 56.6 years) for age, 7.2 to 10.2% (55 to 88 mmol/mol) (median 8.3% (67 mmol/mol)) for HbA1c, 26.2 to 34.4 kg/m² (median 31.2 kg/m²) for body mass index, and 4.7 to 13.0 years (median 9.0 years) for duration of diabetes. Analyses were conducted on the full analysis set or intention-to-treat in 36 studies, per protocol in 3 studies, and not reported in 1 study. Details of medications used in each study are provided

in supplementary table 1. Of the 33 studies with a dual therapy arm, 27 included a placebo. The quality of studies was rated “good” in 93% of the trials (Supplementary table 2).

HbA1c

A network plot of diabetes treatment combinations for all trials which reported HbA1c and had a treatment duration of 6 to 12 months (20-54 weeks) is presented in Figure 1. Four of the 40 trials included had three arms but two of the trials had two dual therapy arms, hence, 46 direct comparisons were available for comparison among nine therapy combinations (one dual (none/placebo added) and eight triple). Where available, the number of studies per direct comparison between therapy combination pairs ranged from 1 to 13. The triple therapies available for comparison comprised SU, DPP-4, GLP-1, SGLT2, INS, AGI, TZD or MEG added to existing dual therapy.

Compared with none/placebo added to dual therapy, the addition of a third therapy to existing dual therapy resulted in significant additional mean reductions in HbA1c, which ranged from -0.56% [95% confidence intervals: -0.70, -0.42] (-6.2 mmol/mol [-7.7, -4.6]) for DPP-4 to -0.94% [-1.18, -0.70] (-10.3 mmol/mol [-13.0, -7.7]) for TZD (Figure 2). Non-significant mean reductions in HbA1c were observed when AGI or MEG was added to dual therapy. When a third therapy was compared with other third therapies added to existing dual therapy, significant difference was observed between DPP-4 and GLP-1, INS, and TZD (Supplementary table 3). TZD was ranked the most effective in the reduction of HbA1c (SUCRA = 89.6%). There was limited evidence to

suggest inconsistency between studies ($p = 0.80$). Estimates of all pairwise comparisons of triple therapies for HbA1c are provided in Supplementary table 3.

When study arms containing insulin were excluded, 28 studies with 31 direct comparisons were available for seven therapy combinations (MEG was not studied in these trials). TZD remained the most effective in the reduction of HbA1c (SUCRA = 89.2%). Of note, however, the point estimate of the mean reduction in HbA1c for SU was 0.4% (4.4 mmol/mol) greater than in the analysis of all studies (from -0.59% [-0.90, -0.28] (6.5 mmol/mol [-9.9, 3.1]) to -0.99% [-1.32, -0.66] (-10.9 [-14.5, -7.3])) and its relative ranking improved with SUCRA value increasing from 43.8% to 87.1%.

In the 34 studies with around 6 months treatment duration, 38 direct comparisons were available for nine therapy combinations. The overall conclusion did not differ when compared with the 6 to 12 months results. Removal of three studies that were rated “poor” also did not alter the conclusion.

Body weight

Body weight was reported in 27 two-arm studies and 4 three-arm studies (2 with two dual therapy arms), which resulted in 37 direct comparisons available for eight therapy combinations (data were not available for AGI). Compared with none/placebo added to dual therapy, a more favourable weight difference was observed for GLP-1 (-1.85 kg [-2.81, -0.89]) and SGLT-2 (-1.79

kg [-3.03, -0.55]) (Figure 3). There was, however, evidence of inconsistency between direct and indirect evidence ($p < 0.0001$). According to the SUCRA values for body weight and HbA1c, the two drug classes (TZD, INS) that ranked highest for their effectiveness in the reduction of HbA1c ranked poorly for body weight due to their effect on weight gain (Figure 4). GLP-1 (73.7% and 91.9%) and SGLT-2 (57.3% and 90.6%) have relatively high SUCRA values for both HbA1c and body weight. Estimates of all pairwise comparisons of triple therapies for body weight are provided in Supplementary table 4. Network meta-regression was not performed to investigate whether baseline mean weight was a possible explanation for inconsistency due to the limited studies available for each comparison. However, there was no systematic ordering (higher to lower) of baseline mean weight weighted by sample size according to the order of mean difference in body weight (weight reduction to weight gain) between triple therapy combinations when compared with none/placebo added to dual therapy.

Similar results were obtained when study arms containing insulin were removed from analysis. For sensitivity analysis of studies with about 6 months treatment duration, similar results were observed except that the mean difference in body weight became non-significant for SU (0.90 kg [-0.40, 2.20]) and there was limited evidence to suggest inconsistency ($p = 0.53$).

Hypoglycaemia

Twenty-seven studies reported the number of participants that experienced at least one episode of mild, or worse, hypoglycaemia during the treatment period, which resulted in 33 direct comparisons available for nine therapy combinations. Estimates of all pairwise

comparisons of triple therapies for hypoglycaemia are provided in Supplementary table 5. Compared with none/placebo added to dual therapy, the odds of hypoglycaemia were higher for DPP-4 (1.95 [1.15, 3.29]), SGLT2 (2.27 [1.07, 4.82]), GLP-1 (2.61 [1.42, 4.79]), TZD (2.83 [1.22, 6.57]), and INS (5.94 [2.80, 12.60]). There was limited evidence of inconsistency between studies ($p = 0.61$).

When study arms containing insulin were removed from analysis, the odds of hypoglycaemia also became significantly higher for SU (11.54 [4.75, 27.99]). For studies with about six months treatment duration, only GLP-1 (2.46 [1.24, 4.88]) and INS (3.80 [1.62, 8.89]) were associated with greater odds of hypoglycaemia than none/placebo added to dual therapy.

Discussion

This is the first study which estimated and compared the effectiveness of all triple therapy combinations that have been studied in randomised trials, not limited to those that included both MET and SU [2], on HbA1c and the associated effect on body weight and hypoglycaemia. There is general consensus that additional reduction in HbA1c can be achieved by adding a third therapy to existing dual therapy treatment. Gross et al reported a 0.70% (7.7 mmol/mol; acarbose) to 1.08% (11.9 mmol/mol; INS) additional absolute HbA1c reduction with a third therapy added to MET/SU compared with MET/SU [2] and in the present study we found an additional 0.56% (6.2 mmol/mol; DPP-4) to 0.94% (10.3 mmol/mol; TZD) HbA1c reduction for a third therapy added to an existing dual therapy. This reduction in HbA1c is clinically relevant. The UK Prospective Diabetes Study reported a 37% reduction in the risk of microvascular

complications and 14% reduction in the risk of myocardial infarction for each 1% (11 mmol/mol) reduction in HbA1c [48]. For a difference of 0.8% (9 mmol/mol) in HbA1c, the Action in Diabetes and Vascular Disease: Preterax and Diamicon Modified Release Controlled Evaluation (ADVANCE) trial reported a 14% reduction in the risk of major microvascular events [49]. A meta-analysis on the effects of glucose lowering and cardiovascular disease, which included ADVANCE, found that a difference of 0.88% (9.7 mmol/mol) in HbA1c was associated with a 9% reduction in the risk of a major cardiovascular event [50].

The specific question addressed by our study was whether there were clinically relevant differences between the various currently available triple therapy combinations. We found no statistical difference in the reduction of HbA1c between six of the drug classes added as a third therapy to existing dual therapy when compared with dual therapy. However, differences were observed between DPP-4 and GLP-1, INS, and TZD when triple therapies were compared.

These changes in HbA1c should be considered in the context of other clinically relevant effects. Estimates of all pairwise comparisons of triple therapies for HbA1c, body weight and hypoglycaemia provided in Supplementary tables 3 to 5 can potentially be used to assist in the selection of drug class as add on to existing dual therapy. For example, compared with DPP-4 (a common first choice added to existing dual therapy), GLP-1 is associated with a 0.25% (2.8 mmol/mol) significantly greater absolute reduction in HbA1c and a 1.9 kg significantly more favourable weight change. In contrast, compared with DPP-4, INS is associated with a 0.35% (3.9 mmol/mol) significantly greater reduction in HbA1c but also a significant 2.3 kg weight gain.

Furthermore, there are also clinically relevant differences in risk of hypoglycaemia between the various therapeutic agents [1,51].

The major strength of this study was that we have compared the relative effects of nine drug classes as add-ons to existing dual therapy on the reduction of HbA1c. However, we were unable to conduct in depth analyses of potential confounders due to the limited number of studies available for each pairwise comparison. For instance, the differences in baseline mean age, body mass index, body weight, HbA1c and duration of diabetes among the 40 trials may have influenced the estimates but we were unable to conduct network meta-regression to explore the effects that these differences may have had on our results. Nevertheless, the baseline mean HbA1c weighted by sample size were similar between drug classes, which ranged from 8.3% (67 mmol/mol) to 8.5% (69 mmol/mol) except for MEG (7.5% (59 mmol/mol)), SGLT2 (8.1% (65 mmol/mol)) and AGI (8.8% (73 mmol/mol)). The lack of direct evidence between drug classes also meant that most comparisons were estimated through direct evidence from one or two studies and indirect evidence. We tested for the overall inconsistency in the network using a global method, yet we were unable to test loop specific inconsistency since most pairwise comparisons only have one study [52]. Furthermore, we have combined study arms that had the same drug class combinations but the drugs used within the same drug class differed among studies, although differences between drugs within the same class are mostly related to adverse effects, rather than in their efficacy in reducing HbA1c. Therefore, it is clinically plausible to combine studies that used different drugs within the same drug class. We have also combined all existing dual therapy combinations since, in clinical practice, a third therapy is only added

when existing dual therapy is no longer effective in controlling blood glucose. The effect of a drug class such as DPP-4 added to any existing dual therapy combinations should result in similar mean difference in HbA1c. We were unable to estimate the odds of severe hypoglycaemia associated with these triple therapy combinations as few studies reported these severe events. Moreover, hypoglycaemia data were the least robust as non-standardised definitions and grading were used.

Clinically relevant additional reduction in HbA1c can be achieved with triple therapy. As described above, the estimates provided in this study may be used to guide clinical practice since it is unlikely that a randomised trial will compare all triple therapy combinations included here. Nevertheless, readers should be aware of the limitations in this study and treat these estimates as a general guide rather than precise evidence.

Acknowledgments

We would like to thank Dr Larry Distiller (Centre for Diabetes & Endocrinology (Pty) Ltd), Dr Valentina Lukashevich (Novartis Pharmaceuticals Corporation) and a representative from Boehringer Ingelheim Pty Limited for providing additional information. M. Woodward is supported by the National Health and Medical Research Council Principal Research Fellowship.

Conflict of interest

M. Woodward has received payment for consultation from Sanofi-Aventis. S. Colagiuri has served on advisory boards and / or received speaking fees from the following:

Astra Zenica, Bristol-Myers Squibb, Glaxo Smith Kline, Janssen-Cilag, Merck Sharp & Dohme, Medtronic, Novartis, Novo Nordisk, Sanofi-aventis, Servier, and Takeda.

References

1. Gunton JE, Cheung NW, Davis TM, Zoungas S, Colagiuri S. A new blood glucose management algorithm for type 2 diabetes. A position statement of the Australian Diabetes Society. *Med J Aust* 2014; 201: 650-3.
2. Gross JL, Kramer CK, Leitaó CB, Hawkins N, Viana LV, Schaan BD et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: A network meta-analysis. *Ann Intern Med* 2011; 154: 672-9.
3. Hollander P, Raslova K, Skjoth TV, Rastam J, Liutkus JF. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. *Diabetes Obes Metab* 2011; 13: 268-75.
4. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015; 162: 777-84.
5. Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? *Control Clin Trials* 1996; 17: 1-12.

6. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. *BMJ* 2005; 331: 897-900.
7. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. *PLOS One* 2013; 8: e76654.
8. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* 2011; 64: 163-71.
9. Standl E, Schernthaner G, Rybka J, Hanefeld M, Raptis SA, Naditch L. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. *Diabetes Res Clin Pract* 2001; 52: 205-13.
10. Yale J-F, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL; the Troglitazone Triple-Therapy Study Group. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2001; 134: 737-45.
11. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; the GWAA study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. *Ann Intern Med* 2005; 143: 559-69.
12. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care* 2005; 28: 1083-91.

13. Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther* 2005; 27: 1535-47.
14. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G; the Insulin Glargine 4014 Study Investigators. Triple therapy in type 2 diabetes. Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. *Diabetes Care* 2006; 29: 554-9.
15. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; the Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. *Diabetes Obes Metab* 2007; 9: 733-45.
16. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. *Diabetologia* 2007; 50: 259-67.
17. Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Liapis CD, Alevizos M. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with type 2 diabetes mellitus. *Diabet Med* 2008; 25: 333-40.
18. Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V; NovoLog Mix-vs.-Exenatide Study Group. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in

subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. *Curr Med Res Opin* 2009; 25: 65-75.

19. Juurinen L, Tiikkainen M, Saltevo J, Nikkila K, Lanki H, Leppavuori E et al. Nateglinide combination therapy with basal insulin and metformin in patients with type 2 diabetes. *Diabet Med* 2009; 26: 409-15.
20. Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R et al. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts). *Diabetes Obes Metab* 2009; 11: 27-32.
21. Russell-Jones D, Vaag A, Schmitz Q, Sethi BK, Lalic N, Antic S et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomized controlled trial. *Diabetologia* 2009; 52: 2046-55.
22. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). *Diabetes Care* 2009; 32: 1224-30.
23. DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of exenatide plus rosiglitazone on β -cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. *Diabetes Care* 2010; 33: 951-7.

24. Liutkus J, Rosas Guzman J, Norwood P, Pop L, Northrup J, Cao D et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinedione alone or in combination with metformin. *Diabetes Obes Metab* 2010; 12: 1058-65.
25. Vilsboll T, Rosenstock J, Yki-Jarvinen H, Cefalu WT, Chen Y, Luo E et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2010; 12: 167-77.
26. Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. *Diabetes Obes Metab* 2011; 13: 1088-96.
27. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. *Diabet Med* 2011; 28: 1352-61.
28. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. *Curr Med Res Opin* 2012; 28: 513-23.
29. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. *J Clin Endocrinol Metab* 2012; 97: 1615-22.
30. DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by

randomized addition of basal insulin prompted by A1C targets. *Diabetes Care* 2012; 35: 1446-54.

31. Violante R, Oliveira HA, Yoon K-H, Reed VA, Yu BM, Bachmann OP et al. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. *Diabet Med* 2012; 29: e417-24.
32. Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Piccinni MN et al. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β -cell function: the triple oral therapy. *Diabet Med* 2013; 30: 846-54.
33. Dobs AS, Goldstein BJ, Aschner P, Horton ES, Umpierrez GE, Duran L et al. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. *J Diabetes* 2013; 5: 68-79.
34. Fonseca V, Staels B, Morgan II JD, Shentu Y, Golm GT, Johnson-Levonas AO et al. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. *J Diabetes Complications* 2013; 27: 177-83.
35. Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes. A 24-week, randomized, double-blind, placebo-controlled trial. *Diabetes Care* 2013; 36: 3396-404.

36. Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. *Diabetes Obes Metab* 2013; 15: 252-7.
37. Liu S-C, Chien K-L, Wang C-H, Chen W-C, Leung C-H. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea. *Endocr Pract* 2013; 19: 980-8.
38. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea, A 52-week randomized trial. *Diabetes Care* 2013; 36: 2508-15.
39. Wilding JP, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruysse F et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomized trial. *Int J Clin Pract* 2013; 67: 1267-82.
40. Yki-Jarvinen H, Rosenstock J, Duran-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes. A \geq 52-week randomized, double-blind study. *Diabetes Care* 2013; 36: 3875-81.
41. Jabbour SA, Hardy E, Sugg J, Parikh S; the Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicentre, randomized, double-blind, placebo-controlled study. *Diabetes Care* 2-14; 37: 740-50.
42. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone

plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. *Diabetes Obes Metab* 2014; 16: 147-58.

43. Lukashevich V, Del Prato S, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. *Diabetes Obes Metab* 2014; 16: 403-9.
44. Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. *Diabetes Obes Metab* 2014; 16: 443-50.
45. Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). *Diabetes Care* 2014; 37: 2159-67.
46. Home PD, Shamanna P, Stewart M, Yang F, Miller M, Perry C et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. *Diabetes Obes Metab* 2015; 17: 179-87.
47. Matthaai S, Bowering K, Rohwedder K, Grohl A, Parikh S; the Study 05 Group. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: A 24-week randomized, double-blind clinical trial. *Diabetes Care* 2015; 38: 365-72.

48. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observation study. *BMJ* 2000; 321: 405-12.
49. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008; 358: 2560-72.
50. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia* 2009; 52: 2288-98.
51. Singh S. Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy. *Curr Diab Rep* 2014; 14: 563.
52. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. *Res Syn Meth* 2012; 3: 98-110.

Figures




Figure 1: Network plot of available diabetes treatment combinations for studies with a treatment duration of 6 to 12 months (20-54 weeks)

The number of studies available per direct comparison is provided in the network. The size of the node reflects the number of studies available for the therapy combination.





Figure 2: Mean difference in HbA1c (%)* of drug classes added to existing dual therapy compared with placebo/none added to dual therapy for studies with a treatment duration of 6 to 12 months (20-54 weeks)

*Multiply HbA1c values by 11 to convert HbA1c in DCCT (%) to IFCC (mmol/mol)



*CI = confidence interval

Figure 3: Mean difference in body weight (kg) of drug classes added to existing dual therapy compared with placebo/none added to dual therapy for studies with a treatment duration of 6 to 12 months (20-54 weeks)




Figure 4: Surface under the cumulative ranking curve (SUCRA) values of HbA1c by body weight for all triple therapies with data for HbA1c and body weight for studies with a treatment duration of 6 to 12 months (20-54 weeks)

Higher SUCRA values for HbA1c indicate greater effectiveness in the reduction of HbA1c. Likewise, higher SUCRA values for body weight indicate greater effectiveness in the reduction of body weight.

Table 1: Characteristics of included studies

Study	Country	Study arms included in analysis (Combinations by drug class)	Sample size	Treatment duration	Female (%)	Mean diabetes duration (years)	Baseline mean			Analysis set used in study
							Age (years)	HbA1c (%) (mmol/mol)	BMI (kg/m ²)	
Standl et al, 2001 [9]	4 countries	MET/SU/AGI MET/SU	n ₁ = 65 n ₂ = 68	24 weeks	47	8.5	61.5	8.8 (73)	27.8	PP
Yale et al, 2001 [10]	Canada	MET/SU/TZD MET/SU	n ₁ = 101 n ₂ = 99	24 weeks	44	11.4	59.0	9.6 (81)	30.1	FAS/ITT
Heine et al, 2005 [11]	13 countries	MET/SU/GLP-1 MET/SU/INS	n ₁ = 282 n ₂ = 267	26 weeks	44	9.6	58.9	8.2 (66)	31.4	FAS/ITT and PP
Kendall et al, 2005 [12]	USA	MET/SU/GLP-1 MET/SU	n ₁ = 241 n ₂ = 247	30 weeks	42	9.1	55.5	8.5 (69)	34	FAS/ITT
Roberts et al, 2005 [13]	USA	MET/SU/TZD MET/TZD	n ₁ = 82 n ₂ = 77	26 weeks	38	8.3	56.5	8.2 (66)	33.4	FAS/ITT
Rosenstock et al, 2006 [14]	USA	MET/SU/TZD MET/SU/INS	n ₁ = 112 n ₂ = 104	24 weeks	48	8.3	55.6	8.7 (72)	34.1	FAS/ITT
Hermansen et al, 2007 [15]	Multi-national	MET/SU/DPP-4 MET/SU	n ₁ = 116 n ₂ = 113 (52% of entire cohort)	24 weeks	48	9.9	57.1	8.3 (67)	31.0	FAS/ITT
Nauck et al, 2007 [16]	13 countries	MET/SU/GLP-1 MET/SU/INS	n ₁ = 253 n ₂ = 248	52 weeks	49	9.9	58.5	8.6 (71)	30.4	FAS/ITT and PP
Kadoglou et al, 2008 [17]	-	MET/SU/TZD MET/SU	n ₁ = 35 n ₂ = 35	26 weeks	57	8.0	65.3	8.1 (65)	29.7	-
Bergenstal et al, 2009 [18]	USA	MET/SU/GLP-1 MET/SU/INS MET/INS	n ₁ = 124 n ₂ = 124 n ₃ = 124	24 weeks	52	9.0	52.6	10.2 (88)	33.8	FAS/ITT
Juurinen et al, 2009 [19]	Finland	MET/INS/MEG MET/INS	n ₁ = 40 n ₂ = 41	24 weeks	45	9.4	56.0	7.4 (57)	32.8	FAS/ITT
Raskin et al, 2009 [20]	USA	MET/INS/TZD MET/TZD	n ₁ = 102 n ₂ = 98	34 weeks	58	8.8	53.8	8.1 (65)	32.9	FAS/ITT
Russell-Jones et al,	17	MET/SU/GLP-1	n ₁ = 230	26 weeks	43	9.4	57.5	8.3	30.5	FAS/ITT

2009 [21]	countries	MET/SU/INS MET/SU	n ₂ = 232 n ₃ = 114					(67)		
Zinman et al, 2009 [22]	2 countries	MET/GLP-1/TZD MET/TZD	n ₁ = 178 n ₂ = 177	26 weeks	44	9	55	8.5 (69)	33.7	FAS/ITT
DeFronzo et al, 2010 [23]	USA	MET/GLP-1/TZD MET/GLP-1 MET/TZD	n ₁ = 47 n ₂ = 45 n ₃ = 45	20 weeks	49	4.7	56	7.8 (62)	32.5	FAS/ITT
Liutkus et al, 2010 [24]	5 countries	MET/GLP-1/TZD MET/TZD	n ₁ = 105 n ₂ = 52 (95% of entire cohort)	26 weeks	41	6.3	54.7	8.2 (66)	33.7	FAS/ITT
Vilsboll et al, 2010 [25]	23 countries	MET/DPP-4/INS MET/INS	n ₁ = 229 n ₂ = 233 (72% of entire cohort)	24 weeks	49	12.5	57.7	8.6 (71)	31	FAS/ITT
Bosi et al, 2011 [26]	Multi-national	MET/DPP-4/TZD MET/TZD	n ₁ = 404 n ₂ = 399	52 weeks (interim data for 26 weeks)	48	7.2	55.1	8.2 (66)	31.5	PP
Hollander et al, 2011 [3]	8 countries	MET/DPP-4/INS MET/SU/DPP-4	n ₁ = 80 n ₂ = 85 (76% of entire cohort)	26 weeks	46	9.8	56.9	8.5 (69)	31.9	FAS/ITT
Owens et al, 2011 [27]	11 countries	MET/SU/DPP-4 MET/SU	n ₁ = 792 n ₂ = 263	24 weeks	53	73% >5 years	58.1	8.1 (65)	28.3	FAS/ITT
Barnett et al, 2012 [28]	10 countries	MET/DDP-4/INS Met/INS	n ₁ = 209 n ₂ = 105 (69% of entire cohort)	24 weeks	59	11.9	57.2	8.7 (72)	32.3	FAS/ITT
DeFronzo et al, 2012 [29]	20 countries	MET/DPP-4/TZD MET/TZD	n ₁ = 780 n ₂ = 388 (75% of entire cohort)	26 weeks	56	6.4	54.5	8.5 (69)	31.2	FAS/ITT
DeVries et al, 2012 [30]	9 countries	MET/GLP-1/INS MET/GLP-1	n ₁ = 162 n ₂ = 161	26 weeks	45	8.6	57.0	7.6 (60)	34.4	FAS/ITT
Violante et al, 2012 [31]	7 countries	MET/DPP-4/GLP-1 MET/GLP-1	n ₁ = 128 n ₂ = 127	20 weeks	50	8	56	7.9 (63)	31.2	PP
Derosa et al, 2013 [32]	Italy	MET/DPP-4/TZD MET/SU/TZD	n ₁ = 228 n ₂ = 225	52 weeks	50	-	-	7.2 (55)	27.5	FAS/ITT
Dobs et al, 2013 [33]	Multi-national	MET/DPP-4/TZD MET/TZD	n ₁ = 170 n ₂ = 92	54 weeks	43	9.3	54.5	8.8 (73)	30.3	FAS/ITT
Fonseca et al, 2013	12	MET/DPP-4/TZD	n ₁ = 157	26 weeks	38	9.8	56.0	8.8	29.9	FAS/ITT

[34]	countries	MET/TZD	n ₂ = 156					(73)		
Haring et al, 2013 [35]	12 countries	MET/SU/SGLT2 MET/SU	n ₁ = 216 n ₂ = 225	24 weeks	49	80% >5 years	57.1	8.1 (65)	28.1	FAS/ITT
Kothny et al, 2013 [36]	11 countries	MET/DPP-4/INS MET/INS	n ₁ = 139 n ₂ = 137 (62% of entire cohort)	24 weeks	50	13.0	59.2	8.8 (73)	28.9	FAS/ITT
Liu et al, 2013 [37]	Taiwan	MET/SU/TZD MET/SU/DPP-4	n ₁ = 60 n ₂ = 60	24 weeks	63	7.8	59.1	8.4 (68)	26.2	FAS/ITT
Schernthaner et al, 2013 [38]	17 countries	MET/SU/SGLT2 MET/SU/DPP-4	n ₁ = 377 n ₂ = 378	52 weeks	44	9.6	56.7	8.1 (65)	31.6	FAS/ITT
Wilding et al, 2013 [39]	11 countries	MET/SU/SGLT2 MET/SU	n ₁ = 156 n ₂ = 156	52 weeks (interim data for 26 weeks)	50	9.9	56.5	8.1 (65)	33.0	FAS/ITT
Yki-Jarvinen et al, 2013 [40]	19 countries	MET/DPP-4/INS MET/INS	n ₁ = 470 n ₂ = 464 (74% of entire cohort)	24 weeks	48	86% >5 years	60.0	8.3 (67)	31.0	FAS/ITT
Jabbour et al, 2014 [41]	6 countries	MET/DPP-4/SGLT2 MET/DPP-4	n ₁ = 113 n ₂ = 113 (51% of entire cohort)	24 weeks	41	6.6	56.7	7.9 (63)	-	FAS/ITT
Kovacs et al, 2014 [42]	8 countries	MET/SGLT2/TZD MET/TZD	n ₁ = 127 n ₂ = 124 (75% of entire cohort)	24 weeks	47	43% >5 years	54.4	8.1 (65)	29.2	FAS/ITT
Lukashevich et al, 2014 [43]	11 countries	MET/SU/DPP-4 MET/SU	n ₁ = 158 n ₂ = 160	24 weeks	52	7.3	55.1	8.8 (73)	28.0	FAS/ITT
Moses et al, 2014 [44]	6 countries	MET/SU/DPP-4 MET/SU	n ₁ = 129 n ₂ = 128	24 weeks	40	-	57.0	8.3 (67)	29.3	FAS/ITT
Wysham et al, 2014 [45]	3 countries	MET/GLP-1/TZD MET/TZD	n ₁ = 276 n ₂ = 141	52 weeks (Placebo only included in first 26 weeks)	43	9	55	8.1 (65)	33.7	FAS/ITT
Home et al, 2015 [46]	9 countries	MET/SU/GLP-1 MET/SU/TZD MET/SU	n ₁ = 271 n ₂ = 277 n ₃ = 115	52 weeks	47	8.9	55.2	8.2 (66)	32.2	FAS/ITT
Matthaei et al, 2015 [47]	6 countries	MET/SU/SGLT2 MET/SU	n ₁ = 108 n ₂ = 108	24 weeks	51	9.5	61.0	8.2 (66)	32.0	FAS/ITT

AGI=alpha glucosidase inhibitor; BMI=body mass index; DPP-4=dipeptidyl peptidase 4 inhibitor; FAS/ITT=full analysis set or intention-to-treat; FBG=fasting blood glucose; FPG=fasting plasma glucose; GLP-1=Glucagon-like peptide-1 receptor agonist; HbA1c=glycated haemoglobin; INS=insulin; MEG=meglitinide; MET=metformin; PP=per protocol; SGLT2=sodium-glucose linked transporter protein 2 inhibitor; SU=sulfonylurea; TZD=thiazolidinedione;

Appendix

Full electronic search strategy for PubMed

("biguanides"[MeSH Terms] OR "biguanides"[All Fields]) OR ("metformin"[MeSH Terms] OR "metformin"[All Fields]) OR ("sulphonamides"[All Fields] OR "sulfonamides"[MeSH Terms] OR "sulfonamides"[All Fields]) OR ("sulfonylurea compounds"[MeSH Terms] OR ("sulfonylurea"[All Fields] AND "compounds"[All Fields]) OR "sulfonylurea compounds"[All Fields] OR "sulfonylureas"[All Fields]) OR ("glyburide"[MeSH Terms] OR "glyburide"[All Fields] OR "glibenclamide"[All Fields]) OR ("glyburide"[MeSH Terms] OR "glyburide"[All Fields]) OR ("gliclazide"[MeSH Terms] OR "gliclazide"[All Fields]) OR ("glimepiride"[Supplementary Concept] OR "glimepiride"[All Fields]) OR ("glipizide"[MeSH Terms] OR "glipizide"[All Fields]) OR ("glycoside hydrolase inhibitors"[Pharmacological Action] OR "glycoside hydrolase inhibitors"[MeSH Terms] OR ("glycoside"[All Fields] AND "hydrolase"[All Fields] AND "inhibitors"[All Fields]) OR "glycoside hydrolase inhibitors"[All Fields] OR ("alpha"[All Fields] AND "glucosidase"[All Fields] AND "inhibitors"[All Fields]) OR "alpha glucosidase inhibitors"[All Fields]) OR ("acarbose"[MeSH Terms] OR "acarbose"[All Fields]) OR ("voglibose"[Supplementary Concept] OR "voglibose"[All Fields]) OR ("miglitol"[Supplementary Concept] OR "miglitol"[All Fields]) OR ("thiazolidinediones"[MeSH Terms] OR "thiazolidinediones"[All Fields]) OR TZD[All Fields] OR ("thiazolidinediones"[MeSH Terms] OR "thiazolidinediones"[All Fields] OR "glitazones"[All Fields]) OR ("pioglitazone"[Supplementary Concept] OR "pioglitazone"[All Fields]) OR ("rosiglitazone"[Supplementary Concept] OR "rosiglitazone"[All Fields]) OR ("dipeptidyl-peptidase iv inhibitors"[Pharmacological Action] OR "dipeptidyl-peptidase iv inhibitors"[MeSH Terms] OR ("dipeptidyl-peptidase"[All Fields] AND "iv"[All Fields] AND "inhibitors"[All Fields]) OR "dipeptidyl-peptidase iv inhibitors"[All Fields] OR "dipeptidyl peptidase 4 inhibitors"[All Fields]) OR (dpp-4[All Fields] AND ("antagonists and inhibitors"[Subheading] OR ("antagonists"[All Fields] AND "inhibitors"[All Fields]) OR "antagonists and inhibitors"[All Fields] OR "inhibitors"[All Fields])) OR ("dipeptidyl-peptidase iv inhibitors"[Pharmacological Action] OR "dipeptidyl-peptidase iv inhibitors"[MeSH Terms] OR

("dipeptidyl-peptidase"[All Fields] AND "iv"[All Fields] AND "inhibitors"[All Fields]) OR "dipeptidyl-peptidase iv inhibitors"[All Fields] OR "gliptins"[All Fields]) OR ("alogliptin"[Supplementary Concept] OR "alogliptin"[All Fields]) OR ("Linagliptin"[Supplementary Concept] OR "Linagliptin"[All Fields] OR "linagliptin"[All Fields]) OR ("saxagliptin"[Supplementary Concept] OR "saxagliptin"[All Fields]) OR ("sitagliptin"[Supplementary Concept] OR "sitagliptin"[All Fields]) OR ("vildagliptin"[Supplementary Concept] OR "vildagliptin"[All Fields]) OR (("sodium, dietary"[MeSH Terms] OR ("sodium"[All Fields] AND "dietary"[All Fields]) OR "dietary sodium"[All Fields] OR "sodium"[All Fields] OR "sodium"[MeSH Terms]) AND ("glucose"[MeSH Terms] OR "glucose"[All Fields]) AND co-transporter[All Fields] AND ("antagonists and inhibitors"[Subheading] OR ("antagonists"[All Fields] AND "inhibitors"[All Fields]) OR "antagonists and inhibitors"[All Fields] OR "inhibitors"[All Fields])) OR (sglt2[All Fields] AND ("antagonists and inhibitors"[Subheading] OR ("antagonists"[All Fields] AND "inhibitors"[All Fields]) OR "antagonists and inhibitors"[All Fields] OR "inhibitors"[All Fields])) OR ("canagliflozin"[Supplementary Concept] OR "canagliflozin"[All Fields]) OR ("2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol"[Supplementary Concept] OR "2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol"[All Fields] OR "dapagliflozin"[All Fields]) OR ("empagliflozin"[Supplementary Concept] OR "empagliflozin"[All Fields]) OR ("glucagon-like peptide-1 receptor"[Supplementary Concept] OR "glucagon-like peptide-1 receptor"[All Fields] OR "glp 1 receptor"[All Fields]) AND ("agonists"[Subheading] OR "agonists"[All Fields])) OR (("incretins"[Pharmacological Action] OR "incretins"[MeSH Terms] OR "incretins"[All Fields] OR "incretin"[All Fields]) AND analogues[All Fields]) OR ("exenatide"[Supplementary Concept] OR "exenatide"[All Fields]) OR ("liraglutide"[Supplementary Concept] OR "liraglutide"[All Fields]) OR ("rGLP-1 protein"[Supplementary Concept] OR "rGLP-1 protein"[All Fields] OR "albiglutide"[All Fields]) OR ("ZP10A peptide"[Supplementary Concept] OR "ZP10A peptide"[All Fields] OR "lixisenatide"[All Fields]) OR ("insulin"[MeSH Terms] OR "insulin"[All Fields]) OR ("meglitinide"[Supplementary Concept] OR "meglitinide"[All Fields]) OR ("nateglinide"[Supplementary Concept] OR "nateglinide"[All Fields]) OR

("repaglinide"[Supplementary Concept] OR "repaglinide"[All Fields])) AND ("diabetes mellitus, type 2"[MeSH Terms] OR "type 2 diabetes mellitus"[All Fields] OR "type 2 diabetes"[All Fields]) AND ("clinical trial"[Publication Type] OR "clinical trials as topic"[MeSH Terms] OR "clinical trial"[All Fields])

Full electronic search strategy for the Cochrane Library

'((biguanides) OR (metformin) OR (sulfonamides) OR (sulfonylureas) OR (glibenclamide) OR (glyburide) OR (gliclazide) OR (glimepiride) OR (glipizide) OR (alpha glucosidase inhibitors) OR (acarbose) OR (voglibose) OR (miglitol) OR (thiazolidinediones) OR (TZD) OR (glitazones) OR (pioglitazone) OR (rosiglitazone) OR (dipeptidyl peptidase 4 inhibitors) OR (dpp-4 inhibitors) OR (gliptins) OR (alogliptin) OR (linagliptin) OR (saxagliptin) OR (sitagliptin) OR (vildagliptin) OR (sodium glucose co-transporter inhibitors) OR (sglt2 inhibitors) OR (canagliflozin) OR (dapagliflozin) OR (empagliflozin) OR (glp-1 receptor agonists) OR (incretin analogues) OR (exenatide) OR (liraglutide) OR (albiglutide) OR (lixisenatide) OR (insulin) OR (meglitinide) OR (nateglinide) OR (repaglinide)) AND (type 2 diabetes) AND (clinical trial) in Trials'

Supplementary table 1: Description of medications used in each study arm

Study	Study arms		
	1	2	3 or more
Standl et al, 2001 [9]	<u>Metformin</u> At least one 500-850 mg per tablet daily <u>Glibenclamide</u> 2-4 tablets (3.5 or 5 mg per tablet) <u>Miglitol</u> 25 mg tid for 4 weeks, 50 mg tid for 4 weeks, then 50 or 100 mg tid	<u>Metformin</u> At least one 500-850 mg per tablet daily <u>Glibenclamide</u> 2-4 tablets (3.5 or 5 mg per tablet) <u>Placebo</u>	
Yale et al, 2001 [10]	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Troglitazone</u> 400 mg/day	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Placebo</u>	
Heine et al, 2005 [11]	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Exenatide</u> 5 µg bid for 4 weeks, then 10 µg bid	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Insulin glargine</u> 10 U/d then titrated to achieve FBG<5.6 mmol/L on daily glucose monitoring	
Kendall et al, 2005 [12]	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Randomized to either maximally effective or minimum recommended dose <u>Exenatide</u> 10 µg bid	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Randomized to either maximally effective or minimum recommended dose <u>Placebo</u>	(Not included) As for arm 1 with Exenatide in 5 µg dosage
Roberts et al, 2005 [13]	<u>Metformin</u> Prestudy level <u>Thiazolidinedione</u> Prestudy level <u>Glimepiride</u> 2 mg/day	<u>Metformin</u> Prestudy level <u>Thiazolidinedione</u> Prestudy level <u>Placebo</u>	
Rosenstock et al, 2006 [14]	<u>Metformin</u> 2000 mg/day <u>Sulfonylurea</u> Prestudy level <u>Rosiglitazone</u> 4 mg/day for 6 weeks, then 4-8 mg/day	<u>Metformin</u> 2000 mg/day <u>Sulfonylurea</u> Prestudy level <u>Insulin glargine</u> 10 IU/day for 7 days, then titrated to achieve FPG <5.5-6.7 mmol/L	
Hermansen et al, 2007 [15]	<u>Metformin</u> 1500-3000 mg/day <u>Glimepiride</u> 4-8 mg/day <u>Sitagliptin</u> 100 mg qd	<u>Metformin</u> 1500-3000 mg/day <u>Glimepiride</u> 4-8 mg/day <u>Placebo</u>	
Nauck et al, 2007 [16]	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Exenatide</u> 5 µg bid for 4 weeks, then 10 µg bid	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Premixed insulin</u> bid	
Kadoglou et al, 2008 [17]	<u>Metformin</u> Prestudy level <u>Gliclazide</u> Prestudy level <u>Rosiglitazone</u> 8 mg/day	<u>Metformin</u> Prestudy level <u>Gliclazide</u> Prestudy level	
Bergental et al,	<u>Metformin</u> Prestudy level	<u>Metformin</u> Prestudy level	<u>Metformin</u> Prestudy level

2009 [18]	<u>Sulfonylurea</u> Prestudy level <u>Exenatide</u> 5 µg bid for 4 weeks, then 10 µg bid	<u>Sulfonylurea</u> Prestudy level <u>Biphasic insulin</u> 12 U qd	<u>Biphasic insulin</u> 6 U bid
Juurinen et al, 2009 [19]	<u>Metformin</u> 500 mg/day <u>Basal insulin</u> Titrated to achieve FPG 4-5.5 mmol/L <u>Nateglinide</u> 120 mg tid	<u>Metformin</u> 500 mg/day <u>Basal insulin</u> Titrated to achieve FPG 4-5.5 mmol/L <u>Placebo</u>	
Raskin et al, 2009 [20]	<u>Metformin</u> 2500 mg/day <u>Pioglitazone</u> 30 or 45 mg/day <u>BIAsp 30</u> 6 units bid titrated every 3-4 days to achieve FPG and pre-evening meal PG 4.4-6.1 mmol/L	<u>Metformin</u> 2500 mg/day <u>Pioglitazone</u> 30 or 45 mg/day	
Russell-Jones et al, 2009 [21]	<u>Metformin</u> 2000 mg/day <u>Glimepiride</u> 4 mg/day <u>Liraglutide</u> 0.6 mg qd with weekly increments of 0.6 mg reaching final daily dose of 1.8 mg	<u>Metformin</u> 2000 mg/day <u>Glimepiride</u> 4 mg/day <u>Insulin glargine</u> Titrated twice weekly to achieve FPG≤5.5 mmol/L	<u>Metformin</u> 2 g/day <u>Glimepiride</u> 4 mg/day <u>Placebo</u>
Zinman et al, 2009 [22]	<u>Metformin</u> 1000 mg bid <u>Rosiglitazone</u> 4 mg bid <u>Liraglutide</u> 1.8 mg qd	<u>Metformin</u> 1000 mg bid <u>Rosiglitazone</u> 4 mg bid <u>Placebo</u>	(Not included) As for arm 1 with Liraglutide in 1.2 mg dosage
DeFronzo et al, 2010 [23]	<u>Metformin</u> Prestudy level <u>Exenatide</u> 5 µg bid for 4 weeks, then 10 µg bid <u>Rosiglitazone</u> 2 mg bid 4 weeks, then 4 mg bid	<u>Metformin</u> Prestudy level <u>Exenatide</u> 5 µg bid for 4 weeks, then 10 µg bid	<u>Metformin</u> Prestudy level <u>Rosiglitazone</u> 2 mg bid 4 weeks, then 4 mg bid
Liutkus et al, 2010 [24]	<u>Metformin</u> Prestudy level <u>Thiazolidinedione</u> Prestudy level <u>Exenatide</u> 5 µg bid for 4 weeks, then 10 µg bid	<u>Metformin</u> Prestudy level <u>Thiazolidinedione</u> Prestudy level <u>Placebo</u>	
Vilsboll et al, 2010 [25]	<u>Metformin</u> Prestudy level <u>Insulin</u> Prestudy level <u>Sitagliptin</u> 100 mg qd	<u>Metformin</u> Prestudy level <u>Insulin</u> Prestudy level <u>Placebo</u>	
Bosi et al, 2011 [26]	<u>Metformin</u> ≥1500 mg/day <u>Pioglitazone</u> 30 mg/day <u>Alogliptin</u> 25 mg/day	<u>Metformin</u> ≥1500 mg/day <u>Pioglitazone</u> 45 mg/day <u>Placebo</u>	
Hollander et al, 2011 [3]	<u>Metformin</u> Prestudy level <u>Sitagliptin</u> 100 mg/day <u>Insulin detemir</u> Titrated weekly to achieve pre-breakfast PG 4.0-6.0 mmol/L	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Sitagliptin</u> 100 mg/day	
Owens et al, 2011 [27]	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Linagliptin</u> 5 mg qd	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Placebo</u>	
Barnett et al, 2012	<u>Metformin</u> Prestudy level	<u>Metformin</u> Prestudy level	

[28]	<u>Insulin</u> Prestudy level <u>Saxagliptin</u> 5 mg/day	<u>Insulin</u> Prestudy level <u>Placebo</u>	
DeFronzo et al, 2012 [29]	<u>Metformin</u> ≤1500 mg/day <u>Pioglitazone</u> 15, 30 or 45 mg/day <u>Alogliptin</u> 12.5 or 25 mg/day	<u>Metformin</u> ≤1500 mg/day <u>Pioglitazone</u> 15, 30 or 45 mg/day	(Not included) Arm 3 Metformin + Alogliptin Arm 4 Metformin + placebo
DeVries et al, 2012 [30]	<u>Metformin</u> Prestudy level <u>Liraglutide</u> 1.8 mg/day <u>Insulin detemir</u> 10 U titrated weekly to achieve FPG 4.1-6.0 mmol/L	<u>Metformin</u> Prestudy level <u>Liraglutide</u> 1.8 mg/day	
Violante et al, 2012 [31]	<u>Metformin</u> Prestudy level <u>Exenatide</u> 5 µg bid for 4 weeks, then 10 µg bid <u>Sitagliptin</u> 100 mg qd	<u>Metformin</u> Prestudy level <u>Exenatide</u> 5 µg bid for 4 weeks, then 10 µg bid <u>Placebo</u>	
Derosa et al, 2013 [32]	<u>Metformin</u> 2200 mg/day <u>Pioglitazone</u> 30 mg/day <u>Sitagliptin</u> 100 mg/day	<u>Metformin</u> 2200 mg/day <u>Pioglitazone</u> 30 mg/day <u>Glibenclamide</u> 5 mg tid	
Dobs et al, 2013 [33]	<u>Metformin</u> 1500-2550 mg/day <u>Rosiglitazone</u> 4-8 mg/day <u>Sitagliptin</u> 100 mg/day	<u>Metformin</u> 1500-2550 mg/day <u>Rosiglitazone</u> 4-8 mg/day <u>Placebo</u>	
Fonseca et al, 2013 [34]	<u>Metformin</u> 1500-2550 mg/day <u>Pioglitazone</u> 30-45 mg/day <u>Sitagliptin</u> 100 mg/day	<u>Metformin</u> 1500-2550 mg/day <u>Pioglitazone</u> 30-45 mg/day <u>Placebo</u>	
Haring et al, 2013 [35]	<u>Metformin</u> ≥1500 mg/day <u>Sulfonylurea</u> Maximum recommended or tolerated dose <u>Empagliflozin</u> 25 mg/day	<u>Metformin</u> ≥1500 mg/day <u>Sulfonylurea</u> Maximum recommended or tolerated dose <u>Placebo</u>	(Not included) As for arm 1 with Empagliflozin in 10 mg dosage
Kothny et al, 2013 [36]	<u>Metformin</u> ≥1500 mg <u>Insulin</u> ≤1 U/kg/day <u>Vildagliptin</u> 50 mg bid	<u>Metformin</u> ≥1500 mg <u>Insulin</u> ≤1 U/kg/day <u>Placebo</u>	
Liu et al, 2013 [37]	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Pioglitazone</u> 30 mg/day	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Sitagliptin</u> 100 mg/day	
Scherthaner et al, 2013 [38]	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Canagliflozin</u> 300 mg qd	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Sitagliptin</u> 100 mg qd	
Wilding et al, 2013 [39]	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level	(Not included) As for arm 1 with canagliflozin

	<u>Canagliflozin</u> 300 mg/day	<u>Placebo</u>	in 100 mg dosage
Yki-Jarvinen et al, 2013 [40]	<u>Metformin</u> Prestudy level <u>Basal insulin</u> Prestudy level <u>Linagliptin</u> 5 mg/day	<u>Metformin</u> Prestudy level <u>Basal insulin</u> Prestudy level <u>Placebo</u>	
Jabbour et al, 2014 [41]	<u>Metformin</u> ≥1500 mg/day <u>Sitagliptin</u> 100 mg/day <u>Dapagliflozin</u> 10 mg	<u>Metformin</u> ≥1500 mg/day <u>Sitagliptin</u> 100 mg/day <u>Placebo</u>	
Kovacs et al, 2014 [42]	<u>Metformin</u> Prestudy level <u>Pioglitazone</u> Prestudy level <u>Empagliflozin</u> 25 mg qd	<u>Metformin</u> Prestudy level <u>Pioglitazone</u> Prestudy level <u>Placebo</u>	(Not included) As for arm 1 with empagliflozin in 10 mg dosage
Lukashevich et al, 2014 [43]	<u>Metformin</u> ≥1500 mg/day <u>Glimepiride</u> ≥4 mg/day <u>Vildagliptin</u> 50 mg bid	<u>Metformin</u> ≥1500 mg/day <u>Glimepiride</u> ≥4 mg/day <u>Placebo</u>	
Moses et al, 2014 [44]	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Saxagliptin</u> 5 mg qd	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Placebo</u>	
Wysham et al, 2014 [45]	<u>Metformin</u> 1500-3000 mg/day <u>Pioglitazone</u> 30-45 mg/day <u>Exenatide</u> 5 µg bid for 4 weeks, then 10 µg bid	<u>Metformin</u> 1500-3000 mg/day <u>Pioglitazone</u> 30-45 mg/day <u>Placebo</u> Once weekly	(Not included) <u>Arm 3</u> as for arm 2 replacing placebo with dulaglutide 1.5 mg once weekly <u>Arm 4</u> as for arm 3 with dulaglutide in 0.75 mg dosage
Home et al, 2015 [46]	<u>Metformin</u> Prestudy level <u>Glimepiride</u> 4 mg/day <u>Albiglutide</u> 30 mg/week	<u>Metformin</u> Prestudy level <u>Glimepiride</u> 4 mg/day <u>Pioglitazone</u> 30 mg/day	<u>Metformin</u> Prestudy level <u>Glimepiride</u> 4 mg/day <u>Placebo</u>
Matthaei et al, 2015 [47]	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Dapagliflozin</u> 10 mg qd	<u>Metformin</u> Prestudy level <u>Sulfonylurea</u> Prestudy level <u>Placebo</u>	

Supplementary table 2: Quality of included studies

Study	Jadad Scale [5]							Total score	Quality
	Was the study described as randomized (this includes the use of words such as randomly, random, and randomization)?	Was the method used to generate the sequence of randomization described and appropriate (table of random numbers, computer generated, etc.)?	Deduct one point if the method used to generate the sequence of randomization was described and it was inappropriate (patients were allocated alternately, or according to date of birth, hospital number, etc.).	Was the study described as double blind?	Was the method of double blinding described and appropriate (identical placebo, active placebo, dummy, etc.)?	Deduct one point if the study was described as double blind but the method of blinding was inappropriate (e.g. comparison of tablet vs. injection with no double dummy).	Was there a description of withdrawals and dropouts?		
	Yes=1, No=0	Yes=1, No=0	<i>Described but inappropriate=-1, Described and appropriate=0</i>	Yes=1, No=0	Yes=1, No=0	<i>Described but inappropriate=-1, described and appropriate=0</i>	Yes=1, No=0		<i>Score 0-2= Poor quality, Score 3-5= Good quality</i>
Standl et al, 2001 [9]	1	0	N/A	1	1	0	1	4	Good
Yale et al, 2001 [10]	1	1	0	1	1	0	1	5	Good
Heine et al, 2005 [11]	1	1	0	0	0	N/A	1	3	Good
Kendall et al, 2005 [12]	1	0	N/A	1	1	0	1	4	Good
Roberts et al, 2005 [13]	1	1	-1	1	1	0	1	4	Good
Rosenstock et al, 2006 [14]	1	0	N/A	0	0	N/A	1	2	Poor
Hermansen et al, 2007 [15]	1	1	0	1	1	0	1	5	Good
Nauck et al, 2007 [16]	1	1	0	0	0	N/A	1	3	Good
Kadoglou et al, 2008 [17]	1	0	N/A	0	0	N/A	1	2	Poor
Bergental et al, 2009 [18]	1	1	0	0	0	N/A	1	3	Good
Juurinen et al, 2009 [19]	1	1	0	1	1	0	1	5	Good
Raskin et al, 2009 [20]	1	0	N/A	0	0	N/A	1	2	Poor
Russell-Jones et al, 2009 [21]	1	1	0	1	1	-1	1	4	Good

Zinman et al, 2009 [22]	1	1	0	1	1	0	1	5	Good
DeFronzo et al, 2010 [23]	1	1	0	0	0	N/A	1	3	Good
Liutkus et al, 2010 [24]	1	1	-1	1	1	0	1	4	Good
Viltsboll et al, 2010 [25]	1	1	0	1	1	0	1	5	Good
Bosi et al, 2011 [26]	1	0	N/A	1	1	0	1	4	Good
Hollander et al, 2011 [3]	1	1	0	0	0	N/A	1	3	Good
Owens et al, 2011 [27]	1	0	N/A	1	1	0	1	4	Good
Barnett et al, 2012 [28]	1	1	0	1	1	0	1	5	Good
DeFronzo et al, 2012[29]	1	0	N/A	1	1	0	1	4	Good
DeVries et al, 2012 [30]	1	1	0	0	0	N/A	1	3	Good
Violante et al, 2012 [31]	1	0	N/A	1	1	0	1	4	Good
Derosa et al, 2013 [32]	1	1	0	1	1	0	1	5	Good
Dobs et al, 2013 [33]	1	1	0	1	1	0	1	5	Good
Fonseca et al, 2013 [34]	1	0	N/A	1	1	0	1	4	Good
Haring et al, 2013 [35]	1	1	0	1	1	0	1	5	Good
Kothny et al, 2013 [36]	1	1	0	1	1	0	1	5	Good
Liu et al, 2013 [37]	1	1	0	0	0	N/A	1	3	Good
Schernthaner et al, 2013 [38]	1	1	0	1	1	0	1	5	Good
Wilding et al, 2013 [39]	1	1	0	1	1	0	1	5	Good
Yki-Jarvinen et al, 2013 [40]	1	1	0	1	1	0	1	5	Good
Jabbour et al, 2014 [41]	1	0	N/A	1	1	0	1	4	Good
Kovacs et al, 2014 [42]	1	1	0	1	1	0	1	5	Good
Lukashevich et al, 2014 [43]	1	0	N/A	1	1	0	1	4	Good
Moses et al, 2014 [44]	1	1	-1	1	1	0	1	4	Good
Wysham et al, 2014 [45]	1	1	0	0	1	-1	1	3	Good
Home et al, 2015 [46]	1	1	0	1	1	0	1	5	Good
Matthaei et al, 2015 [47]	1	1	0	1	1	0	1	5	Good

Supplementary table 3: Estimated mean difference (95% confidence intervals) in HbA1c* (%) for all pairwise therapy combinations obtained from consistency model

Third therapy added	None/placebo	SU	DPP-4	GLP-1	SGLT2
None/placebo	None/placebo	-0.59 (-0.90,-0.28)	-0.56 (-0.71,-0.42)	-0.81 (-1.01,-0.62)	-0.69 (-0.92,-0.46)
SU	0.59 (0.28,0.90)	SU	0.03 (-0.29,0.35)	-0.23 (-0.57,0.12)	-0.10 (-0.48,0.28)
DPP-4	0.56 (0.42,0.71)	-0.03 (-0.35,0.29)	DPP-4	-0.25 (-0.49,-0.01)	-0.13 (-0.39,0.13)
GLP-1	0.81 (0.62,1.01)	0.23 (-0.12,0.57)	0.25 (0.01,0.49)	GLP-1	0.12 (-0.18,0.43)
SGLT2	0.69 (0.46,0.92)	0.10 (-0.28,0.48)	0.13 (-0.13,0.39)	-0.12 (-0.43,0.18)	SGLT2
INS	0.91 (0.68,1.13)	0.32 (-0.03,0.66)	0.35 (0.08,0.61)	0.09 (-0.14,0.32)	0.22 (-0.11,0.54)
AGI	0.35 (-0.29,0.99)	-0.24 (-0.95,0.47)	-0.21 (-0.87,0.45)	-0.46 (-1.14,0.21)	-0.34 (-1.02,0.34)
TZD	0.94 (0.69,1.18)	0.35 (-0.03,0.73)	0.38 (0.10,0.65)	0.12 (-0.16,0.41)	0.25 (-0.09,0.58)
MEG	0.37 (-0.26,1.00)	-0.22 (-0.92,0.48)	-0.19 (-0.84,0.45)	-0.44 (-1.10,0.21)	-0.32 (-0.99,0.35)

Third therapy added	INS	AGI	TZD	MEG
None/placebo	-0.91 (-1.13,-0.68)	-0.35 (-0.99,0.29)	-0.94 (-1.18,-0.69)	-0.37 (-1.00,0.26)
SU	-0.32 (-0.66,0.03)	0.24 (-0.47,0.95)	-0.35 (-0.73,0.03)	0.22 (-0.48,0.92)
DPP-4	-0.35 (-0.61,-0.08)	0.21 (-0.45,0.87)	-0.38 (-0.65,-0.10)	0.19 (-0.45,0.84)
GLP-1	-0.09 (-0.32,0.14)	0.46 (-0.21,1.14)	-0.12 (-0.41,0.16)	0.44 (-0.21,1.10)
SGLT2	-0.22 (-0.54,0.11)	0.34 (-0.34,1.02)	-0.25 (-0.58,0.09)	0.32 (-0.35,0.99)
INS	INS	0.56 (-0.12,1.24)	-0.03 (-0.33,0.27)	0.54 (-0.13,1.21)
AGI	-0.56 (-1.24,0.12)	AGI	-0.59 (-1.28,0.10)	-0.02 (-0.92,0.88)
TZD	0.03 (-0.27,0.33)	0.59 (-0.10,1.28)	TZD	0.57 (-0.11,1.24)
MEG	-0.54 (-1.21,0.13)	0.02 (-0.88,0.92)	-0.57 (-1.24,0.11)	MEG

*Multiply HbA1c values by 11 to convert HbA1c in DCCT (%) to IFCC (mmol/mol)

AGI=alpha glucosidase inhibitor; DPP-4=dipeptidyl peptidase 4 inhibitor; GLP-1=Glucagon-like peptide-1 receptor agonist; INS=insulin; SGLT2=sodium-glucose linked transporter protein 2 inhibitor; SU=sulfonylurea; TZD= thiazolidinedione;

A positive value suggests that the reduction in HbA1c is worse with the column therapy combination in comparison to the row therapy combination. Likewise, a negative value suggests that the reduction in HbA1c is better with the column therapy combination in comparison to the row therapy combination.

Supplementary table 4: Estimated mean difference (95% confidence intervals) in body weight (kg) for all pairwise therapy combinations obtained from consistency model

Third therapy added	None/placebo	SU	DPP-4	GLP-1	SGLT2
None/placebo	None/placebo	3.23 (1.56,4.90)	0.02 (-0.87,0.92)	-1.85 (-2.81,-0.89)	-1.79 (-3.03,-0.55)
SU	-3.23 (-4.90,-1.56)	SU	-3.21 (-4.94,-1.48)	-5.08 (-7.00,-3.16)	-5.02 (-7.10,-2.94)
DPP-4	-0.02 (-0.92,0.87)	3.21 (1.48,4.94)	DPP-4	-1.88 (-3.17,-0.58)	-1.81 (-3.34,-0.29)
GLP-1	1.85 (0.89,2.81)	5.08 (3.16,7.00)	1.88 (0.58,3.17)	GLP-1	0.06 (-1.50,1.63)
SGLT2	1.79 (0.55,3.03)	5.02 (2.94,7.10)	1.81 (0.29,3.34)	-0.06 (-1.63,1.50)	SGLT2
INS	-2.34 (-3.51,-1.18)	0.89 (-1.14,2.92)	-2.32 (-3.77,-0.87)	-4.19 (-5.32,-3.07)	-4.13 (-5.83,-2.43)
TZD	-2.72 (-3.99,-1.45)	0.51 (-1.56,2.58)	-2.70 (-4.15,-1.25)	-4.57 (-6.02,-3.13)	-4.51 (-6.29,-2.74)
MEG	-0.20 (-3.14,2.74)	3.03 (-0.35,6.41)	-0.18 (-3.25,2.90)	-2.05 (-5.14,1.04)	-1.99 (-5.18,1.20)

Third therapy added	INS	TZD	MEG
None/placebo	2.34 (1.18,3.51)	2.72 (1.45,3.99)	0.20 (-2.74,3.14)
SU	-0.89 (-2.92,1.14)	-0.51 (-2.58,1.56)	-3.03 (-6.41,0.35)
DPP-4	2.32 (0.87,3.77)	2.70 (1.25,4.15)	0.18 (-2.90,3.25)
GLP-1	4.19 (3.07,5.32)	4.57 (3.13,6.02)	2.05 (-1.04,5.14)
SGLT2	4.13 (2.43,5.83)	4.51 (2.74,6.29)	1.99 (-1.20,5.18)
INS	INS	0.38 (-1.15,1.91)	-2.14 (-5.31,1.02)
TZD	-0.38 (-1.91,1.15)	TZD	-2.52 (-5.73,0.68)
MEG	2.14 (-1.02,5.31)	2.52 (-0.68,5.73)	MEG

AGI=alpha glucosidase inhibitor; DPP-4=dipeptidyl peptidase 4 inhibitor; GLP-1=Glucagon-like peptide-1 receptor agonist; INS=insulin; SGLT2=sodium-glucose linked transporter protein 2 inhibitor; SU=sulfonylurea; TZD= thiazolidinedione;

A positive value indicates that the body weight outcome is worse with the column therapy combination in comparison to the row therapy combination. Likewise, a negative value indicates that the body weight outcome is better with the column therapy combination in comparison to the row therapy combination.


Supplementary table 5: Estimated odds ratios (95% confidence intervals) of hypoglycaemia for all pairwise therapy combinations obtained from consistency mode

Third therapy added	None/placebo	SU	DPP-4	GLP-1	SGLT2
None/placebo	None/placebo	2.59 (0.90,7.45)	1.95 (1.15,3.29)	2.61 (1.42,4.79)	2.27 (1.07,4.82)
SU	0.39 (0.13,1.11)	SU	0.75 (0.23,2.44)	1.01 (0.30,3.41)	0.88 (0.24,3.21)
DPP-4	0.51 (0.30,0.87)	1.33 (0.41,4.30)	DPP-4	1.34 (0.61,2.94)	1.17 (0.51,2.65)
GLP-1	0.38 (0.21,0.71)	0.99 (0.29,3.36)	0.75 (0.34,1.64)	GLP-1	0.87 (0.33,2.28)
SGLT2	0.44 (0.21,0.93)	1.14 (0.31,4.16)	0.86 (0.38,1.95)	1.15 (0.44,3.01)	SGLT2
INS	0.17 (0.08,0.36)	0.44 (0.12,1.58)	0.33 (0.13,0.80)	0.44 (0.20,0.94)	0.38 (0.13,1.10)
AGI	0.96 (0.02,60.55)	2.47 (0.03,178.76)	1.86 (0.03,121.88)	2.49 (0.04,164.93)	2.17 (0.03,147.07)
TZD	0.35 (0.15,0.82)	0.91 (0.24,3.55)	0.69 (0.27,1.76)	0.92 (0.38,2.26)	0.80 (0.26,2.45)
MEG	0.45 (0.09,2.33)	1.17 (0.17,8.22)	0.88 (0.16,4.92)	1.18 (0.21,6.76)	1.03 (0.17,6.23)

Third therapy added	INS	AGI	TZD	MEG
None/placebo	5.94 (2.80,12.60)	1.05 (0.02,66.23)	2.83 (1.22,6.57)	2.20 (0.43,11.30)
SU	2.30 (0.63,8.35)	0.40 (0.01,29.26)	1.09 (0.28,4.25)	0.85 (0.12,5.98)
DPP-4	3.05 (1.25,7.44)	0.54 (0.01,35.14)	1.45 (0.57,3.70)	1.13 (0.20,6.30)
GLP-1	2.28 (1.06,4.89)	0.40 (0.01,26.58)	1.09 (0.44,2.67)	0.85 (0.15,4.84)
SGLT2	2.61 (0.91,7.52)	0.46 (0.01,31.21)	1.25 (0.41,3.80)	0.97 (0.16,5.87)
INS	INS	0.18 (0.00,11.94)	0.48 (0.19,1.21)	0.37 (0.06,2.25)
AGI	5.68 (0.08,384.58)	AGI	2.70 (0.04,186.44)	2.11 (0.02,182.08)
TZD	2.10 (0.83,5.32)	0.37 (0.01,25.49)	TZD	0.78 (0.12,4.90)
MEG	2.69 (0.45,16.28)	0.47 (0.01,40.98)	1.28 (0.20,8.07)	MEG

AGI=alpha glucosidase inhibitor; DPP-4=dipeptidyl peptidase 4 inhibitor; GLP-1=Glucagon-like peptide-1 receptor agonist; INS=insulin; SGLT2=sodium-glucose linked transporter protein 2 inhibitor; SU=sulfonylurea; TZD= thiazolidinedione;

A value greater than one indicates that the column therapy combination is associated with greater odds of hypoglycaemia than the row therapy combination. A value less than one indicates that the column therapy combination is associated with lower odds of hypoglycaemia than the row therapy combination.



Supplementary figure 1: Flow diagram for identifying eligible studies